Activity of cefditoren against respiratory pathogens

Related Experiment Video

Updated: Sep 30, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Catherine L Clark1, Kensuke Nagai, Bonifacio E Dewasse

  • 1Departments of Pathology (Clinical Microbiology), Hershey Medical Center, Hershey, PA 17033, USA.

The Journal of Antimicrobial Chemotherapy
|July 4, 2002
PubMed

Insights

Cefditoren demonstrated superior activity against resistant Streptococcus pneumoniae and Haemophilus influenzae, showing potent bactericidal effects and low resistance development. This cephalosporin offers a promising option for treating challenging bacterial infections.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Antibiotic resistance in Streptococcus pneumoniae and Haemophilus influenzae is a growing public health concern.
  • Macrolide and quinolone resistance necessitates the evaluation of alternative antibiotic classes.
  • Cephalosporins remain a cornerstone in treating bacterial infections, requiring ongoing assessment of their efficacy against resistant strains.

Purpose of the Study:

  • To evaluate the in vitro activity of cefditoren against contemporary clinical isolates of Streptococcus pneumoniae and Haemophilus influenzae.
  • To compare the bactericidal activity and resistance selection potential of cefditoren with other oral cephalosporins.
  • To determine the minimum inhibitory concentrations (MICs) and time-kill kinetics of cefditoren against key respiratory pathogens.

Main Methods:

  • Minimum inhibitory concentration (MIC) testing against 250 Streptococcus pneumoniae and 160 Haemophilus influenzae isolates.
  • Time-kill studies to assess bactericidal activity at various concentrations.
  • Multistep and single-step resistance selection studies to evaluate mutant prevention potential.

Main Results:

  • Cefditoren exhibited the lowest MICs against all tested pneumococcal strains, including penicillin-resistant isolates.
  • Time-kill studies showed cefditoren achieved rapid and extensive killing of pneumococci and Haemophilus influenzae.
  • Cefditoren, along with amoxiclav and cefprozil, did not select for resistant mutants, unlike cefuroxime and azithromycin.

Conclusions:

  • Cefditoren displays potent in vitro activity against drug-resistant Streptococcus pneumoniae and Haemophilus influenzae.
  • Its bactericidal effect and low propensity to select for resistance make it a valuable therapeutic option.
  • Cefditoren represents an important advancement in managing infections caused by challenging bacterial pathogens.

More Related Videos

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

Related Concept Videos

Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...